8.33
Precedente Chiudi:
$8.33
Aprire:
$8.28
Volume 24 ore:
306.35K
Relative Volume:
0.82
Capitalizzazione di mercato:
$491.59M
Reddito:
-
Utile/perdita netta:
$-153.16M
Rapporto P/E:
-2.2575
EPS:
-3.69
Flusso di cassa netto:
$-134.48M
1 W Prestazione:
+7.21%
1M Prestazione:
+6.25%
6M Prestazione:
-21.04%
1 anno Prestazione:
-58.99%
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Nome
Cullinan Therapeutics Inc
Settore
Industria
Telefono
617-410-4650
Indirizzo
ONE MAIN STREET, CAMBRIDGE
Confronta CGEM con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
CGEM
Cullinan Therapeutics Inc
|
8.33 | 478.61M | 0 | -153.16M | -134.48M | -3.69 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-06-11 | Ripresa | Stifel | Buy |
2024-10-24 | Iniziato | UBS | Buy |
2024-05-01 | Iniziato | Stifel | Buy |
2024-04-15 | Iniziato | William Blair | Outperform |
2024-02-15 | Iniziato | Wedbush | Outperform |
2023-06-15 | Iniziato | TD Cowen | Outperform |
2022-11-21 | Iniziato | BTIG Research | Buy |
2021-04-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2021-02-02 | Iniziato | Evercore ISI | Outperform |
2021-02-02 | Iniziato | Morgan Stanley | Equal-Weight |
2021-02-02 | Iniziato | SVB Leerink | Outperform |
2021-02-01 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Cullinan Therapeutics Inc Borsa (CGEM) Ultime notizie
What drives Cullinan Therapeutics Inc. stock priceAccelerated investment success - Autocar Professional
Is Cullinan Therapeutics Inc. a good long term investmentUnbelievable profit margins - Autocar Professional
Breakthrough Lung Cancer Treatment: Zipalertinib Trial Results Reveal New Hope for Hard-to-Treat EGFR Mutations - Stock Titan
What analysts say about Cullinan Therapeutics Inc. stockExplosive market performance - jammulinksnews.com
Cullinan Therapeutics Inc. Stock Analysis and ForecastExceptional stock performance - jammulinksnews.com
Zipalertinib's NDA Submission: Can Cullinan Therapeutics Finally Cash In on Its Breakthrough? - AInvest
Cullinan Therapeutics: Betting On Zipalertinib NDA Catalyst - Seeking Alpha
How Cullinan Therapeutics Inc. stock performs during market volatilityChart Breakout Alert - Newser
Why Cullinan Therapeutics Inc. stock attracts strong analyst attentionBalanced Risk Reward Portfolio - Newser
What makes Cullinan Therapeutics Inc. stock price move sharplyFree Stock Market Expert Consultation - Newser
Disc Medicine Appoints Nadim Ahmed To Board - citybiz
Disc Medicine Appoints Nadim Ahmed to its Board of Directors - The Manila Times
We're Keeping An Eye On Cullinan Therapeutics' (NASDAQ:CGEM) Cash Burn Rate - Yahoo Finance
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Cullinan Oncology stock rating reiterated at Buy by Clear Street - Investing.com Australia
Cullinan Therapeutics, Inc.(NasdaqGS:CGEM) dropped from Russell Microcap Growth Index - MarketScreener
Assenagon Asset Management S.A. Cuts Stock Position in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Asia Deal Watch: SunRock, Escugen Collaborate On CCR9-Targeted ADC - insights.citeline.com
Cullinan deals $712M to test Genrix bispecific TCE in autoimmune - BioWorld MedTech
Analysts Set Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Target Price at $30.00 - Defense World
Cullinan Management Holds Annual Stockholders Meeting - TipRanks
Another BiTE in autoimmune: Cullinan deals $712M for Genrix asset - BioWorld MedTech
California State Teachers Retirement System Lowers Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Now Covered by Analysts at Stifel Nicolaus - Defense World
Stifel Reinstates Cullinan Therapeutics (CGEM) with Buy Rating a - GuruFocus
Stifel Reinstates Cullinan Therapeutics (CGEM) with Buy Rating and $22 Price Target | CGEM Stock News - GuruFocus
Stifel Recommends Buy Rating for Cullinan Therapeutics (CGEM) | CGEM Stock News - GuruFocus
Two Sigma Investments LP Has $514,000 Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Squarepoint Ops LLC Sells 11,673 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
The week in pharma: action, reaction and insight – week to June 6 - The Pharma Letter
Two Sigma Advisers LP Grows Stake in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics Licenses Rights to Velinotamig from Genrix Bio - Contract Pharma
Cullinan Therapeutics Stock Slides After-Hours Despite $692M Autoimmune Drug Pact With Genrix By Stocktwits - Investing.com India
Cullinan Therapeutics Inc Azioni (CGEM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):